^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | Gastric Adenocarcinoma |
| Drug: | Enweida (envafolimab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
First-line envafolimab plus SOX chemotherapy for PD-L1 positive metastatic or recurrent gastric adenocarcinoma: A multi-centre, single-arm phase II clinical trial.
Published date:
05/25/2023
Excerpt:
This multi-centre, single-arm, open-label study was conducted to evaluate the efficacy and safety of Envafolimab in metastatic or recurrent gastric adenocarcinoma... key inclusion criteria were previously untreated, HER2-negative, PD-L1 positive….The ORR was 50%, and DCR was 87.5%, based on RECIST v1.1....Envafolimab plus chemotherapy is a promising and tolerable therapeutic regimen for patients with metastatic or recurrent gastric adenocarcinoma.
Secondary therapy:
SOX
DOI:
10.1200/JCO.2023.41.16_suppl.e16029
Trial ID:
